Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 4/20 | 0.49 |
| ▸ | DRD5 | P21918 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188753 | 1.00 | MAOA (0.55) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| Hydrochloric Acid SCHEMBL4513459 | 0.98 | MAOA (0.57) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| SCHEMBL30561544 | 0.94 | MAOA (0.59) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| SCHEMBL218317 | 0.94 | MAOA (0.59) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| Hydrochloric Acid SCHEMBL4521948 | 0.92 | MAOA (0.60) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| SCHEMBL216418 | 0.92 | DRD1 (0.51) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| Hydrochloric Acid SCHEMBL4591079 | 0.90 | DRD1 (0.50) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| Hydrochloric Acid SCHEMBL3773192 | 0.90 | DRD1 (0.50) | MAOAMAOBSLC6A4NR1H2DRD1 | |
| SCHEMBL1951275 | 0.89 | DRD1 (0.49) | MAOAMAOBNR1H2DRD1DRD5 | |
| SCHEMBL188773 | 0.85 | KDM4E (0.43) | MAOAMAOBNR1H2DRD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886824-B | 2, 3-Dihydropyrimido [4,5-d ] pyrimidine-4 (1H) -ketone derivative, preparation method and application thereof | 四川大学华西医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4619407-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | Curadev Pharma Ltd (GB) | 2025-09-24 | — | — | EP | disclosed |
| CN-117843616-B | 3-Cyano-substituted quinoline compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-118176195-A | Pyrazolo [3,4-d ] pyrimidine-3-ketone compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024105363-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116462680-A | Antitumor compound and application thereof | 南京大美生物制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116456985-A | Pyrimidine and pyridine derivatives as HPK1 modulators and methods of use thereof | 深圳市原力生命科学有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022214869-A2 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022063140-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AS HPK1 MODULATOR AND METHODS USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2022-03-31 | — | — | WO | disclosed |
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | ERBB2, ERBB3, ARRB1 | MAOA 2386/4885MAOB 2221/4885SLC6A4 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.